Leder, B. Z., Zapalowski, C., Hu, M., Hattersley, G., Lane, N. E., Singer, A. J., & Dore, R. K. (2019). Fracture and Bone Mineral Density Response by Baseline Risk in Patients Treated With Abaloparatide Followed by Alendronate: Results From the Phase 3 ACTIVExtend Trial. J Bone Miner Res.
Citação norma ChicagoLeder, Benjamin Z., Carol Zapalowski, Ming‐Yi Hu, Gary Hattersley, Nancy E. Lane, Andrea J. Singer, and Robin K. Dore. "Fracture and Bone Mineral Density Response By Baseline Risk in Patients Treated With Abaloparatide Followed By Alendronate: Results From the Phase 3 ACTIVExtend Trial." J Bone Miner Res 2019.
Citação norma MLALeder, Benjamin Z., et al. "Fracture and Bone Mineral Density Response By Baseline Risk in Patients Treated With Abaloparatide Followed By Alendronate: Results From the Phase 3 ACTIVExtend Trial." J Bone Miner Res 2019.